Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fatiha H Shabaruddin

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Pharmacogenomics|April 27, 2010
Cost-effectiveness analysis in pharmacogenomicsKatherine Payne, Fatiha H Shabaruddin
Pharmacogenomics and Personalized Medicine|August 27, 2015
Economic evaluations of personalized medicine: existing challenges and current developmentsFatiha H Shabaruddin, Nigel D Fleeman, Katherine Payne
Euroasian Journal of Hepato-Gastroenterology|July 3, 2018
Hepatocellular Carcinoma in Malaysia and Its Changing TrendRuksana Raihan, Amirah Azzeri, Fatiha H Shabaruddin, et al.
Pharmacoeconomics|March 27, 2013
A systematic review of utility values for chemotherapy-related adverse eventsFatiha H Shabaruddin, Li-Chia Chen, Rachel A Elliott, et al.
Journal of Virus Eradication|November 23, 2019
Hepatitis C elimination by 2030 in Malaysia: an achievable goal?Rosmawati Mohamed, Fatiha H Shabaruddin, Amirah Azzeri, et al.
Value in Health Regional Issues|March 29, 2019
A Stepwise Approach to a National Hepatitis C Screening Strategy in Malaysia to Meet the WHO 2030 Targets: Proposed Strategy, Coverage, and CostsLindsey Hiebert, Robert Hecht, Shan Soe-Lin, et al.
Public Health Genomics|June 13, 2019
Generic Cost-Effectiveness Models: A Proof of Concept of a Tool for Informed Decision-Making for Public Health Precision MedicineSusan R Snyder, Jing Hao, Larisa H Cavallari, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Pharmacogenomics|April 27, 2010
Cost-effectiveness analysis in pharmacogenomicsKatherine Payne, Fatiha H Shabaruddin
Pharmacogenomics and Personalized Medicine|August 27, 2015
Economic evaluations of personalized medicine: existing challenges and current developmentsFatiha H Shabaruddin, Nigel D Fleeman, Katherine Payne
Euroasian Journal of Hepato-Gastroenterology|July 3, 2018
Hepatocellular Carcinoma in Malaysia and Its Changing TrendRuksana Raihan, Amirah Azzeri, Fatiha H Shabaruddin, et al.
Pharmacoeconomics|March 27, 2013
A systematic review of utility values for chemotherapy-related adverse eventsFatiha H Shabaruddin, Li-Chia Chen, Rachel A Elliott, et al.
Journal of Virus Eradication|November 23, 2019
Hepatitis C elimination by 2030 in Malaysia: an achievable goal?Rosmawati Mohamed, Fatiha H Shabaruddin, Amirah Azzeri, et al.
Value in Health Regional Issues|March 29, 2019
A Stepwise Approach to a National Hepatitis C Screening Strategy in Malaysia to Meet the WHO 2030 Targets: Proposed Strategy, Coverage, and CostsLindsey Hiebert, Robert Hecht, Shan Soe-Lin, et al.
Public Health Genomics|June 13, 2019
Generic Cost-Effectiveness Models: A Proof of Concept of a Tool for Informed Decision-Making for Public Health Precision MedicineSusan R Snyder, Jing Hao, Larisa H Cavallari, et al.
Pageof 1